Fimasartan - Boryung Pharmaceutical
Alternative Names: Arakhor; BR 1007; BR-1017A; BR-A-657; BR-A-657-K; BR1015-1; BR1015-2; BR1017-1; KanarbLatest Information Update: 12 Apr 2024
At a glance
- Originator Boryung
- Developer Boryung; Labcorp Drug Development; R-Pharm
- Class Antihyperlipidaemics; Antihypertensives; Pyrimidinones; Small molecules; Urologics
- Mechanism of Action Angiotensin type 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Essential hypertension; Hypertension
- Phase III Kidney disorders
- No development reported Diabetic nephropathies; Dyslipidaemias; Myocardial infarction
Most Recent Events
- 18 Feb 2024 Boryung Pharmaceutical completes a phase I trial (In volunteers) in South Korea (PO) (NCT06184269)
- 23 Dec 2023 Boryung Pharmaceutical initiates enrolment in a phase I trial (In volunteers) in South Korea (PO) (NCT06184269)
- 06 Oct 2023 Boryung Pharmaceutical completes a phase I trial for Hypertension (In Volunteers) in South Korea (PO, Tablet) (NCT06008028)